- Home
- CRWD vs SNY Comparison
CRWD vs SNY Comparison
Compare CRWD & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRWD
- SNY
- Stock Information
- Founded
- CRWD 2011
- SNY 1994
- Country
- CRWD United States
- SNY France
- Employees
- CRWD N/A
- SNY N/A
- Industry
- CRWD EDP Services
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- CRWD Technology
- SNY Health Care
- Exchange
- CRWD Nasdaq
- SNY Nasdaq
- Market Cap
- CRWD 116.6B
- SNY 116.5B
- IPO Year
- CRWD 2019
- SNY N/A
- Fundamental
- Price
- CRWD $427.90
- SNY $49.77
- Analyst Decision
- CRWD Buy
- SNY Buy
- Analyst Count
- CRWD 47
- SNY 2
- Target Price
- CRWD $459.75
- SNY $65.00
- AVG Volume (30 Days)
- CRWD 2.7M
- SNY 2.7M
- Earning Date
- CRWD 08-27-2025
- SNY 07-31-2025
- Dividend Yield
- CRWD N/A
- SNY 3.21%
- EPS Growth
- CRWD N/A
- SNY 118.56
- EPS
- CRWD N/A
- SNY 8.65
- Revenue
- CRWD $4,136,022,000.00
- SNY $53,714,621,258.00
- Revenue This Year
- CRWD $23.41
- SNY $2.85
- Revenue Next Year
- CRWD $21.83
- SNY $6.65
- P/E Ratio
- CRWD N/A
- SNY $5.76
- Revenue Growth
- CRWD 25.94
- SNY 15.65
- 52 Week Low
- CRWD $242.25
- SNY $44.73
- 52 Week High
- CRWD $517.98
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- CRWD 37.59
- SNY 57.34
- Support Level
- CRWD $419.81
- SNY $48.23
- Resistance Level
- CRWD $442.43
- SNY $47.54
- Average True Range (ATR)
- CRWD 14.97
- SNY 0.80
- MACD
- CRWD -1.94
- SNY 0.23
- Stochastic Oscillator
- CRWD 13.38
- SNY 94.92
About CRWD CrowdStrike Holdings Inc.
CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.